Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans

Transplantation

Volumn 65, Issue 3, 1998, Pages 405-410

  Van Gelder, T ^a   Baan, C C ^a   Balk, A H M M ^a   Knoop, C J ^a   Holweg, C T J ^a   Van Der Meer, P ^a   Mochtar, B ^a   Zondervan, P E ^a   Niesters, H G M ^a   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; TISSUE DONORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032519670     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199802150-00020     Document Type: Article

References (26)

1. Norman DJ, Kahana L, Stuart FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
2. Balk AHMM, Simoons ML, Jutte NHPM, et al. Sequential OKT3 and cyclosporine after heart transplantation: a randomized study with single and cyclic OKT3. Clin Transpl 1991; 5: 301.
3. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
4. Grossi P, DeMaria R, Caroli A, et al. Infections in heart transplant recipients: the experience of the Italian heart transplant program. J Heart Lung Transplant 1992; 11: 847.
5. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
6. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antilymphocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
7. Hourmant M, Le Mauff B, Cantarovich D, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994; 57: 204.
8. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
9. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
10. Cantarovich D, Le Mauff B, Hourmant M, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994; 57: 198.
11. van Gelder T, Balk AHMM, Jonkman FAM, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996; 62: 51-55.
12. Langrehr JM, Nüssler NC, Neumann U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997; 63: 1772.
13. Friend PJ, Waldmann H, Cobbold S, et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplantation 1991; 23: 1390.
14. Tellides G, Dallman MJ, Morris PJ. Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 202.
15. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 207.
16. Van Gelder T, Daane CR, Vaessen LMB, et al. In vitro and in vivo effects of BT563, an anti-interleukin-2 receptor monoclonal antibody. Transpl Int 1994; 7: S556.
17. International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587.
18. Baan CC, van Emmerik NEM, Balk AHMM, et al. Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants. Clin Exp Immunol 1994; 97: 293.
19. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
20. Hesse CJ, van Gelder T, Vaessen LMB, et al. Pharmacodynamics of prophylactic antirejection therapy with an anti-interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation. Immunopharmacology 1995; 30: 237.
21. van Gelder T, Mulder AH, Balk AHMM, et al. Intragraft monitoring of rejection following prophylactic treatment with monoclonal anti interleukin-2receptor antibody (BT563) in heart transplant recipients. J Heart Lung Transplant 1995; 14: 346.
22. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489.
23. Roy-Chaudhury P, Manfro RC, Steiger J, et al. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc 1997; 29: 1083.
24. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62: 543.
25. Amlot P, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
26. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial ot humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33.